Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women

European Journal of Endocrinology

Volumn 156, Issue 5, 2007, Pages 539-545

  Botella Carretero, José I ^a   Alvarez Blasco, Francisco ^a   San Millán, José Luis ^a   Escobar Morreale, Héctor F ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEOXYPYRIDINOLINE; IODINE 131; LIOTHYRONINE; OSTEOCALCIN; OSTEOPROTEGERIN; PYRIDINOLINE; THYROXINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT WITHDRAWAL; URINE LEVEL; WHOLE BODY SCINTISCANNING;

ADULT; AMINO ACIDS; COHORT STUDIES; CREATININE; FEMALE; HUMANS; HYPOTHYROIDISM; OSTEOCALCIN; OSTEOPROTEGERIN; POSTMENOPAUSE; PROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 34249098684     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0649     Document Type: Article

References (25)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R & Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309-319.
2. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T & Higashio K. Isolation of a novel cytokinc from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and Biophysical Research Communications 1997 234 13 7-142.
3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N & Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS 1998 95 3597-3602.
4. Rogers A & Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. Journal of Clinical Endocrinology and Metabolism 2005 90 6323-6331.
5. Indridason OS, Franzson L & Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporosis International 2005 16 417-423.
6. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K & Yamada Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 1999 14 518-527.
7. Mochizuki Y, Banba N, Hattori Y & Monden T. Correlation between serum osteoprotegerin and biomarkers of bone metabolism during anti-thyroid treatment in patients with Graves' disease. Hormone Research 2006 66 236-239.
8. Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, lorio S, Molinari A, Giustina A & Carella C. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004 35 785-791.
9. Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P & Pietschmann P. Receptor activator of nuclear factor kappaB figand and osteoprotegerin in men with thyroid cancer. European Journal of Clinical Investigation 2006 36 566-573.
10. Nagasaki T, Inaba M, Jono S, Hiura Y, Tahara H, Shirakawa K, Onoda N, Ishikawa T, Ishimura E & Nishizawa Y. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. European Journal of Endocrinology 2005 152 347-353.
11. Guang-da X, Hui-ling S, Zhi-song C & Lin-shuang Z. Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. Journal of Clinical Endocrinology and Metabolism 2005 90 5765-5768.
12. Guang-Da X, Hui-Ling S, Zhi-Song C & Lin-Shuang Z. Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. Journal of Endocrinological Investigation 2005 28 965-972.
13. Botella-Carretero JI, Alvarez-Blasco F, Sancho J & Escobar-Morreale HF. Effects of thyroid hormones on serum levels of adipokines as studied in patients with differentiated thyroid carcinoma during thyroxine withdrawal. Thyroid 2006 16 397-402.
14. Botella-Carretero JI, Prados A, Manzano L, Montero MT, Escribano L, Sancho J & Escobar-Morreale HF. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. European Journal of Endocrinology 2005 153 223-230.
15. Botella-Carretero JI, Gomez-Bueno M, Barrios V, Caballero C, Garcia-Robles R, Sancho J & Escobar-Morreale HF. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer 2004 11 345-356.
16. Botella-Carretero JI, Galan JM, Caballero C, Sancho J & Escobar-Morreale HE. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer 2003 10 601-610.
17. Nakamura H, Mori T, Genma R, Suzuki Y, Natsume H, Andoh S, Kitahara R, Nagasawa S, Nishiyama K & Yoshimi T. Urinary excretion of pyridinoline and deoxypyridinoline measured by immunoassay in hypothyroidism. Clinical Endocrinology 1996 44 447-451.
18. Regalbuto C, Alagona C, Maiorana R, Di Paola R, Cianci M, Alagona G, Sapienza S, Vigneri R & Pezzino V. Acute changes in clinical parameters and thyroid function peripheral markers following L-T4 withdrawal in patients totally thyroidectomized for thyroid cancer. Journal of Endocrinological Investigation 2006 29 32-40.
19. Hofbauer LC, Kluger S, Kuhne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A & Heufelder AE. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. Journal of Cellular Biochemistry 2002 86 642-650.
20. Abu EO, Horner A, Teti A, Chatterjee VK & Compston JE. The localization of thyroid hormone receptor mRNAs in human bone. Thyroid 2000 10 287-293.
21. Abe E, Marians: RC, Yu W Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF & Zaidi M. TSH is a negative regulator of skeletal remodeling. Cell 2003 115 151-162.
22. Novack DV. TSH, the bone suppressing hormone. Cell 2003 115 129-130.
23. Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P. Biondi B, Iorio S, Giustina A, Amato G & Carella C. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. Journal of Bone and Mineral Research 2005 20 480-486.
24. Varga F, Spitzer S & Klaushofer K. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcified Tissue International 2004 74 382-387.
25. Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M & Chihara K. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. Journal of Cell Physiology 2004 201 17-25.